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Glioma stem-like cells (GSCs) correspond to a tumor cell subpopulation, involved in glioblastoma multiforme (GBM) tumor ini-
tiation and acquired chemoresistance. Currently, drug-induced differentiation is considered as a promising approach to eradi-
cate this tumor-driving cell population. Recently, the effect of cannabinoids (CBs) in promoting glial differentiation and
inhibiting gliomagenesis has been evidenced. Herein, we demonstrated that cannabidiol (CBD) by activating transient receptor
potential vanilloid-2 (TRPV2) triggers GSCs differentiation activating the autophagic process and inhibits GSCs proliferation
and clonogenic capability. Above all, CBD and carmustine (BCNU) in combination overcome the high resistance of GSCs to
BCNU treatment, by inducing apoptotic cell death. Acute myeloid leukemia (Aml-1) transcription factors play a pivotal role in
GBM proliferation and differentiation and it is known that Aml-1 control the expression of several nociceptive receptors. So,
we evaluated the expression levels of Aml-1 spliced variants (Aml-1a, b and c) in GSCs and during their differentiation. We
found that Aml-1a is upregulated during GSCs differentiation, and its downregulation restores a stem cell phenotype in differ-
entiated GSCs. Since it was demonstrated that CBD induces also TRPV2 expression and that TRPV2 is involved in GSCs differ-
entiation, we evaluated if Aml-1a interacted directly with TRPV2 promoters. Herein, we found that Aml-1a binds TRPV2
promoters and that Aml-1a expression is upregulated by CBD treatment, in a TRPV2 and PI3K/AKT dependent manner. Alto-
gether, these results support a novel mechanism by which CBD inducing TRPV2-dependent autophagic process stimulates
Aml-1a-dependent GSCs differentiation, abrogating the BCNU chemoresistance in GSCs.
Key words: glioblastoma stem-like cells, cannabidiol, differentiation, Aml-1, autophagy, chemosensitivity
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diol; ChIP: chromatin immunoprecipitation; CPZ: capsazepine; CXCR4: C-X-C chemokine receptor type 4; D-GSCs: differentiated GSCs;
EGF: epidermal growth factor; eiF: eukaryotic initiator factors; FACS: fluorescence activated cell sorting analysis; FBS: fetal bovine
serum; FITC: fluorescein isothiocyanate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary acidic protein; GSCs:
glioblastoma stem-like cells; HRP: horseradish peroxidase; JC-1: 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraehylbenzimidazolylcarbocyanineiodide; 3-
MA: 3-methyladenine; LC3: microtubuled-associated protein-1 light chain 3; DWm: mitochondrial transmembrane potential; MTT: 3-
(4,5-dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide; Oct-4: octamer-binding transcription factor 4; PI: propidium iodide; qRT-
PCR: quantitative real-time polymerase chain reaction; RR: ruthenium red; TMZ: temozolomide; TRP: transient receptor potential;
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acetyllactosamine.
Additional Supporting Information may be found in the online version of this article.
†M.N. and M.B.M. contributed equally to this work
Grant sponsor: Italian Minister of Research; Grant number: PRIN2010; Grant sponsor: FIRC (National Grant 2011–2013); Grant number:
11095
DOI: 10.1002/ijc.29573
History: Received 16 Oct 2014; Accepted 15 Apr 2015; Online 21 Apr 2015
Correspondence to: Dr. Massimo Nabissi, School of Pharmacy, University of Camerino, Camerino (MC), Italy, Tel.: 1390737403306,
Fax: 1390737403325, E-mail: massimo.nabissi@unicam.it
C
an
ce
r
C
el
l
B
io
lo
gy
Int. J. Cancer: 137, 1855–1869 (2015) VC 2015 UICC
International Journal of Cancer
IJC
Glioblastoma multiforme (GBM) remains the most deadly
human brain tumor, with a median survival of approximately
1 year.1 GBM presents unique challenges to therapy due to
its location, aggressive biological behavior and diffuse inﬁltra-
tive growth. Despite the development of new surgical techni-
ques, radiotherapy and the use of multiple antineoplastic
drugs, a cure for GBM remains elusive.2,3 Recent studies have
led to the hypothesis that GBM is maintained by a small
population of glioma stem-like cells (GSCs), isolated from
both glioma tissues and glioma cell lines.4 GSCs retain stem
cell properties, are highly tumorigenic, and display increased
resistance to radiation and conventional chemotherapeutic
drugs, as carmustine (bis-chloroethylnitrosourea, BCNU) and
temozolomide (TMZ), thus GSCs are potential key target for
novel GBM therapies.4–7 Recent reports support prodifferentia-
tion as a potential strategy to inhibit GSCs tumorigenicity and
activation of the autophagic process was found to promote
GSCs differentiation and to increase radio and chemosensitiv-
ity.8,9 Cannabinoids, as D9-tetrahydrocannabinol (THC) and
cannabidiol (CBD), were found to inhibit human glioma cell
lines viability.10,11 THC and cannabinoid agonists (HU210,
JWH133) were found to induce autophagy and stimulate GSCs
differentiation by cannabinoid receptors (CBR).10,12,13 Autopha-
gic process is regulated by different autophagy-related genes
(ATGs) and signaling molecules such as mTOR, AKT and class
I and III phosphatidyl-inositol 3-kinase.9 At molecular levels
THC and CBD regulate different key genes involved in auto-
phagic process, as Beclin-1 and AKT signaling in glioma cell
lines,10 while no data about CBD in regulating autophagy in
GSCs were actually provided.
Previously, we have demonstrated that transient receptor
potential vanilloid type 2 (TRPV2), a target receptor for
CBD, impairs GSC proliferation and promotes astroglial dif-
ferentiation in vitro and in vivo.14
The transcriptional network regulating GSCs proliferation
and differentiation is still partially identiﬁed, indicating some
drivers of tumor initiation, as the Runt-related transcription
factor 1 (RunX-1), named Acute myeloid leukemia 1 (Aml-1)
in human.15,16
Aml-1 gene generates at least three alternatively spliced var-
iants: Aml-1a, -b and -c. Aml-1b and Aml-1c possess the
DNA-binding region and the transcriptional regulatory domains
and they are considered similar in functions. Otherwise, Aml-1a
retains the DNA-binding domain but lacks the transcrip-
tional regulatory domains and it is considered a potential
functional antagonist of Aml-1b and Aml-1c.17 Aml-1 gene
has been reported mutated in human cancer, as somatic
point mutations in myelodysplasia and chromosomal translo-
cation in acute myeloid leukaemia.18,19 Aberrant expression
in breast and Aml-1 deletion in esophagus adenocarcinoma
have been documented.20,21 Aml-1 was also found expressed
in human GBM cell lines15 but no information on the role of
Aml-1 and its spliced variants in GBM was deﬁned. In brain,
Aml-1 plays a relevant role in sensory neuron differentiation,
controlling the expression of several sensory nociceptive
receptors, including members of the transient receptor poten-
tial (TRP) class of thermal receptors.22,23
Herein, we provide the ﬁrst evidence on the role of TRPV2
in autophagic-dependent astroglial GSCs differentiation. In
addition, we found that the Aml-1a spliced variant is upregu-
lated during GSCs differentiation, and that its downregulation
restores a stem cell phenotype and proliferation in differenti-
ated GSCs. Finally, we evidenced that Aml-1a promotes
TRPV2 expression, and that Aml-1a is upregulated by CBD.
Material and Methods
Cell cultures
GSC lines (#1, #30 and #83) previously characterized11 were
isolated from surgical samples of three adult patients, diagnosed
according to the WHO classiﬁcation of tumors of the central
nervous system, who had undergone craniotomy at the Insti-
tute of Neurosurgery, Catholic University School of Medicine,
Rome. Informed consent was obtained before surgery according
to the protocols approved. GSC lines were cultured in a serum-
free medium supplemented with 20 ng/ml of epidermal growth
factor (EGF) and 10 ng/ml of basic ﬁbroblast growth factor
(bFGF). For differentiation, GSC lines were grown in medium
supplemented with 5% fetal bovine serum (FBS).
Reagents and antibodies
Cannabidiol (CBD, >98% purity), ruthenium red (RR), capsaze-
pine (CPZ, >99% purity), AM251 (>99% purity), AM630 (>98%
purity) and GW9662 (>98% purity) were purchased from Tocris
Bioscience (Bristol, UK). 5-bromo-2-deoxyuridine (BrdU, 99%
purity), 1,3-bis (2-chloroethyl)-1-nitrosurea (BCNU, 98%
purity) and 3-methyladenine (3-MA,98% purity) were obtained
from Sigma Aldrich (St. Louis, MO). Baﬁlomycin A1 (BAF1,
90% purity) was from Labogen (Milan, Italy). Rapamycin
What’s new?
Glioma stem-like cells (GSCs) are a cell subpopulation that is believed to be involved in glioblastoma multiforme tumor initiation
and acquired chemoresistance. This study shows that cannabidiol acts on GSCs via the Transient Receptor Potential Vanilloid-2
(TRPV2) channel to induce autophagic-dependent inhibition of proliferation, promotion of differentiation, and sensitization to the
cytotoxic effects of alkylating agents. Moreover, the authors identify a transcriptional network that is induced by cannabidiol via
the Aml-1a transcription factor and stimulates TRPV2-dependent inhibition of proliferation and promotion of differentiation in
GSCs. The results suggest a promising approach for regulating the tumor stem-like cell compartment in glioblastoma.
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(98% purity) was from Adipogen (San Diego, CA). The follow-
ing mouse monoclonal antibodies (mAbs) were used: anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-peroxi-
dase (Sigma Aldrich), anti-class III beta-tubulin (bIII-tubulin)
(Millipore, Billerica, MA), anti-Aml-1 (Cell Signaling Technology,
Danvers, MA) and ﬂuorescein isothiocyanate (FITC)-conjugated
anti-BrdU (Becton Dickinson Biosciences, San Jose, CA). The fol-
lowing polyclonal Abs were used: rabbit anti-AKT (Cell Signal-
ing), rabbit anti-pAKT (Cell Signaling), mouse anti-CD133-PE
(Miltenyi, Bergisch, Germany), mouse anti-CXCR4- Pe-cy5
(eBioscience, Hatﬁeld, UK), rabbit anti-glial ﬁbrillary acidic pro-
tein (GFAP), rabbit anti-nestin (Sigma-Aldrich), rabbit anti-Oct-4
(Cell Signaling), mouse anti-SSEA-1-PE (eBioscience), goat anti-
Sox2 (R&D System, Minneapolis, MN), goat anti-TRPV2 (Santa
Cruz Biotechnology, Heidelberg, Germany), rabbit anti-
microtubule-associated protein-1 light chain 3 (LC3, Novus Bio-
logical, Littleton, CO), rabbit anti-Beclin-1 (Cell Signaling Tech-
nology), rabbit anti-Aml-1-Chip grade (Abcam plc, Cambridge,
UK), rabbit Control IgG-CHIP grade (Abcam), rabbit anti-RNA
Polymerase II (Qiagen, Milan, Italy), rabbit anti-TFIIB (Abcam).
The following secondary antibodies were used: horseradish perox-
idase (HRP)-conjugated sheep anti-mouse IgG, HRP-conjugated
donkey anti-goat IgG (Santa Cruz Biotechnology) and HRP-
conjugated donkey anti-rabbit IgG (GE Healthcare, Munich, Ger-
many), PE-conjugated anti-rabbit (Santa Cruz Biotechnology),
PE-conjugated anti-goat (Santa Cruz Biotechnology), PE-
conjugated anti-mouse (Santa Cruz Biotechnology). The follow-
ing isotypes were used: PE-conjugated Mouse IgG1 (Miltenyi),
PE-cy5-conjugated mouse IgG2Ak (eBioscience), PE-conjugated
mouse IgM (eBioscience).
Cell viability
Cell viability was assessed by the 3–(4,5-dimethylthazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay as previously
described.11 3 3 104 cells in 100 ll were seeded in 96-well
plates. After 24 hr of incubation, compounds or vehicles
were added. Four replicates were used for each treatment.
The absorbance of the samples against a background control
(medium alone) was measured at 570 nm using an ELISA
reader microliter plate (BioTek Instruments, Winooski, VT).
Soft agar assay
Sphere-forming/self-renewal capability was tested by soft agar
assay in six-well plate. Brieﬂy, a 500 ll underlayer of 0.6% soft
agarose (sea plaque agarose diluted in medium plus growth
factors) was prepared in each 35-mm well. A total of 3 3 103
cells/well were added above the layer as a second layer com-
posed of 2/3 soft agarose 0.4% and 1/3 cells plus medium in a
total volume of 500 ll. The plates were incubated for 10 min at
4 8C and for 15 days at 37 8C. Then, the dishes were stained
with 70 ll of Crystal Violet (0.1%) and colonies were counted.
BrdU cell proliferation assay
The incorporation of BrdU was assessed using the BrdU Cell
Proliferation Assay (Millipore). 3 3 104 cells in 100 ll were
seeded in 96-well plates and treated with vehicle or CBD.
Incorporated BrdU was detected by adding the peroxidase
substrate, following manufactoring protocol. Spectrophoto-
metric detection was performed at a dual wavelength of 450/
550 nm using an ELISA reader microliter plate. In some
experiment, cells labeled with 20 lM BrdU were ﬁxed with
4% paraformaldehyde and stained with anti-BrdU FITC-con-
jugated Ab as previously described.14
Cell cycle analysis
3 3 105 cells/ml were incubated with the appropriate drugs for
24 hr, in six-wells plates. Cells were ﬁxed in ice-cold 70% etha-
nol, treated for 30 min at 37 8C with 100 lg/ml ribonuclease
A solution (Sigma-Aldrich), stained for 30 min at room tem-
perature with propidium iodide (PI) 20 lg/ml (Sigma-Aldrich)
and analyzed by ﬂow cytometry using linear ampliﬁcation.
Apoptosis assays
The exposure of phosphatidylserine was detected by Annexin-
V staining. 3 3 105 cells/ml were seeded in six-wells plates
and treated with different doses of the appropriate drugs for
24 hr. Four replicates were used for each treatment. After
treatment, cells were stained with 5 ll of Annexin-V FITC
(Enzo Life Sciences, Farmingdale, NY) for 10 min at room
temperature and analyzed on a FACScan ﬂow cytometer using
CellQuest software, as previously described.11
PI incorporation assay
3 3 105 cells/ml were seeded in six-wells plates and treated
with different doses of CBD for 24 hr. After treatment the
cells were incubated in medium containing 20 lg/ml PI for
10 min at room temperature. The cells were then analyzed
by ﬂow cytometry using CellQuest software.
Western blot analysis
3 3 105 cells/ml were seeded in six-wells plates and treated
with different doses of the appropriate drugs. Total proteins
from GSC lines were obtained as previously described.14
Plasma membrane, cytosol and nuclear fractions were iso-
lated using the Subcellular Protein Fractionation kit (Thermo
Scientiﬁc, Rockford, IL), according to the manufacturer’s
directions. 20 lg of the lysate was separated on a SDS-
polyacrylamide gel, transferred onto Hybond-C extra mem-
branes (GE Healthcare), blocked with 5% low-fat dry milk in
PBS-Tween 20, immunoblotted with LC3 (2 mg/mL), Beclin-1
(1:1,000), GFAP (1:300), bIII-tubulin (1:1,000), Nestin
(1:1,000), Sox2 (0.5 mg/mL), anti-Aml-1 (1:1,000), anti-AKT
(1:1,000), anti-pAKT (1:1,000) and anti-TRPV2 (1:200) fol-
lowed by the appropriate HRP-conjugated secondary Abs
(1:2,000). For quantiﬁcation, anti-GAPDH (1:5,000) or anti-
TFIIB (4 lg/ml) Abs was used as loading control. The detec-
tion was performed using the LiteAblot VR PLUS or the LiteA-
blot VR TURBO (EuroClone, Milan, Italy) kits and
densitometric analysis was carried out by a Chemidoc using
the Quantity One software (Bio-Rad).
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Mitochondrial transmembrane potential
Mitochondrial transmembrane potential (DWm) was eval-
uated by 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraehylbenzimidazolyl-
carbocyanineiodide (JC-1) staining. 3 3 105 cells/ml were
seeded in six-wells plate and treated with the appropriate
drugs for 24 hr and then incubated for 10 min at room tem-
perature with 10 lg/ml of JC-1. Carbonyl cyanide chlorophe-
nylhydrazone protonophore (CCCP, 50 lg), a mitochondrial
uncoupler that collapses the DWm was used as a positive con-
trol. JC-1 was excited by an argon laser (488 nm), and the
green (530 nm)/red (570 nm) emission ﬂuorescence was col-
lected simultaneously. Samples were analyzed using a FACS-
can cytoﬂuorimeter with CellQuest software.
Fluorescence-activated cell sorting analysis
3 3 105 cells/ml were seeded in six-wells plate and treated
with the appropriate drugs. GSC lines were labeled with anti-
CD133 (1:10), anti-Oct-4 (1:600), anti-SSEA-1 (0.5 lg/106
cells), anti-Nestin (1:50), anti-Sox2 (1:50), anti-CXCR4 (1:50),
anti-GFAP (1:100), anti-bIII-tubulin (1:50), anti-TRPV2
(1:25) Abs, followed by FITC-conjugated or PE-conjugated
secondary Abs, where necessary. The speciﬁcity of staining
was conﬁrmed using isotype-speciﬁc Abs as negative control.
Samples were analyzed by a FACScan cytoﬂuorimeter using
the CellQuest software (Becton Dickinson). Fluorescence inten-
sity was expressed in arbitrary units on logarithmic scale.
Gene expression analysis
Total RNA was extracted with the RNeasy Mini Kit (Qiagen),
and cDNA was synthesized using the High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, PA) according to
the manufacturer’s instructions. Qualitative PCR were performed
using 50 ng of cDNA diluted in PCR master mix (Promega;
Supporting Information Table S1). The thermal cycler proﬁle
was: 5 min at 95 8C, 35 cycles at 10 sec 95 8C, 20 sec 60 8C, 25
sec 72 8C, followed by 5 min at 72 8C. PCR products were ana-
lyzed in a 1.5% agarose gel electrophoresis. Quantitative real-
time polymerase chain reactions (qRT-PCR) for CB1, CB2,
TRPV1, TRPV2, GPR55, PPARg, Beclin-1 and Aml-1a, b and c
were performed using the iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, CA) as described.11 All
samples were assayed in triplicates in the same plate. Measure-
ment of b-actin levels was used to normalize mRNA contents,
and receptors levels were calculated by the 22DDCt method.
Genes silencing
IBONI siRNA 4-duplexes pools for Aml-1 (siAml-1) isoforms,
3-siRNA duplexed bundle S pools for Aml-1a (siAml-1a) iso-
form and four siRNA duplexed for Beclin-1 were purchased
(Riboxx Life Science, Germany; Supporting Information Table
S2). siCONTROL non-targeting siRNA (siGLO) used as nega-
tive control and siGLO RISC-Free siRNA (siFLUO, a siRNA
non-target Cy3-labeled control siRNA cotransfected with func-
tional siRNA) were purchased from Thermo Scientiﬁc-
Dharmacon (Lafayette, CO). For gene silencing experiments,
GSC lines were plated at the density of 3 3 104/ml in six-wells
plates and incubated in differentiation medium for 7 days in
presence of 160 pmol of siAml-1, siAml-1a, siBeclin-1, siGLO
or siFLUO, following the METAFECTENE SI PRO transfection
protocol (Biontex Laboratories, San Diego, CA).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) studies were per-
formed using EPItech One day kit (Qiagen) following manufac-
turing protocol. For each ChIP assay chromatin from 33 106
cells was fragmented to an average size from 500 to 1,500 bp
by eight rounds of sonication (Power: 0.5 W, Time: 2 sec on, 15
sec off; total time 16 sec) in 2 ml tubes using the Sonicator 3000
(MISONIX, Part # 3000) (QSonica, LLC, Newtown, CT). The
fragmented chromatin was immunoprecipitated, using 4 mg of
anti-Aml-1 Ab-CHIP grade or 4 mg of rabbit control IgG-CHIP
grade as negative control or 4 lg of anti-RNA Polymerase II as
positive control, by incubation on rotator at 14 8C overnight.
Then, the DNA was puriﬁed from the precipitated samples
using QIAquick MinElute (Qiagen) columns, and analyzed by
SYBR green real time PCR using EpiTect ChIP qPCR Assay
(Qiagen) with speciﬁc primers against the proximal region of
human TRPV2 gene promoter sequence (NM_016113.3
(1)08Kb, (1)01Kb), human GAPDH (NM_002046.3
(1)01Kb) and human IGX1A (NC_000012.11(-)01A),
according to manufacturer instructions. Data analysis were
performed using ChIP qPCR Data Analysis Template (Qia-
gen). The speciﬁcity of Aml-1a in regulating TRPV2 promoters
activity was assessed by ChIP analysis and ChIP qPCR Assay
comparing TRPV2 promoters expression levels in siAml-1 D-
GSCs with siAml-1a D-GSCs lines.
qRT-PCR and PCR array
The Human Autophagy and Stem cell Signaling Pathway
Finder PCR Arrays with related reagents were purchased from
SABiosciences (Frederick, MD). Total RNA from untreated or
GSCs treated for 6 hr with vehicle- or CBD in proliferative
medium, and from siGLO- and siAml-1a-transfected differenti-
ated GSC (D-GSC) lines at day 7 post-transfection in differen-
tiative medium, was extracted. 2 lg of total RNA from each
sample were subjected to reverse transcription in a total volume
of 20 ll using the ReactionReady ﬁrst strand cDNA (SABio-
sciences). cDNAs were analyzed by qRT-PCR performed using
a IQ5 Multicolor Real time PCR Detection system, the SuperAr-
ray’s RT2 real-time SYBR Green PCR Master Mix and the rela-
tive array, according to manufacturer’s instructions.
Measurement of two housekeeping genes (GAPDH; Ribosomal
protein, large, P0; RPLP0) on the samples was used to normalize
mRNA content. The gene expression levels of CBD-treated
GSCs or siAml-1a-transfected GSCs were expressed as relative
fold compared with untreated or vehicle-treated GSCs or
siGLO-transfected D-GSCs. Data acquisition was performed
using the web-based integrated PCR Array Data Analysis Tem-
235 plate provided by SABiosciences.
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DNA methylation analysis
The assessment of the methylation status of MGMT promoter
was performed in GSC lines, using DNA modiﬁcation and
AMPLI-MGMT kit (Diachem, Naple, IT), following manufac-
turer instructions. Before Methylation-speciﬁc PCR assay,
genomic DNA was extracted using DNA extraction kit (Qiagen)
and subjected to sodium Bisulﬁte Conversion of Unmethylated
Cytosines using EpiTech Bisulﬁte kit (Qiagen). PCR products
were separated by 2% agarose gel electrophoresis in the presence
of ethidium bromide and visualized under UV illumination.
Statistical analysis
The data presented represent the mean and standard devia-
tion (SD) of at least 3 independent experiments. The statisti-
cal signiﬁcance was determined by analysis of variance
(ANOVA) or Student’s t test; *, #p< 0.01. The statistical analy-
sis of IC50 levels was performed using Prism 5.01 (Graph Pad).
Data from untreated cells were omitted because no differences
were observed between vehicle-treated and untreated cells.
Results
CBD affects GSC lines viability in a TRPV2-dependent
manner
GSC lines (#1, #30, #83) were treated with CBD (from 0.5 to 50
lM) up to three days and cell viability was analyzed by MTT
assay. CBD induced a signiﬁcant decrease of cell viabilty (Sup-
porting Information Fig. S1) with an IC50 of 19.4 lM (#1), 14.6
lM (#30) and 19.3 lM (#83) at 24 hr post-treatment (Fig. 1a).
The lowest effective dose of CBD (10 lM) was used for the sub-
sequent experiments. Then we evaluated the expression of CB1
and CB2, and CB-related receptors, such as TRPV1, TRPV2,
GPR55 and PPARg in GSC lines, by qRT-PCR. The results
demonstrated the expression of the CB1, CB2, TRPV1 and
Figure 1. Effect of CBD on GSC cell lines viability. (a) GSC #1, #30 and #83 cell lines were cultured for 24 hr with different doses of CBD. Cell
viability was determined by MTT assay. Data shown are expressed as mean6SE of three separate experiments. (b) GSC #1, #30 and #83 cells
were pretreated with AM251 (10 lM), AM630 (10 lM), RR (25 lM), CPZ (1 lM) and tranilast (50 lM) for 1 hr and then cultured for 24 hr with
CBD (10 lM). Cell viability was determined by MTT assay. Data shown are expressed as mean6SD of three separate experiments; *p<0.01
CBD vs. vehicle. #p<0.01 treatments vs. CBD. (c) The relative TRPV2 mRNA expression in GSC #83 cells treated with vehicle or 10 lM CBD
was evaluated by qRT-PCR. TRPV2 mRNA levels were normalized for b-actin expression. Data are expressed as mean6SD. *p<0.01 vs. vehi-
cle. (d) Lysates from GSC #83 cells treated with 10 lM CBD were separated on 7% SDS-PAGE and probed with anti-TRPV2 and anti-GAPDH
Abs, respectively. Blots are representative of one of three separate experiments. Numbers represent the densitometric analysis as compared
with GAPDH. Data shown are relative to GSC #83 line and are representative of the three GSC lines analyzed.
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Figure 2:
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TRPV2 mRNA (Supporting Information Fig. S2), but not of the
GPR55 and PPAR-g mRNA (data not shown). Thereafter, the
involvement of these expressed receptors in CBD-mediated
effects, was evaluated by pretreating for 1 hr the GSC lines with
10 lM AM251 (CB1 selective antagonist), 10 lM AM630 (CB2
selective antagonist), 10 lM RR (TRP channel blocker), 10 lM
CPZ (TRPV1 selective antagonist) and 50 lM tranilast (TRPV2
selective antagonist), before the addition of 10 lM CBD, one
day post-treatment by MTT assay. The results showed that only
RR and tranilast are able to revert the CBD effects (Fig. 1b),
indicating that in GSC lines, CBD inhibits viability in a CB1-,
CB2- and TRPV1-independent but TRPV2-dependent manner.
Moreover, by qRT-PCR and western blot analysis we
showed a signiﬁcant increase of TRPV2 expression after treat-
ment with CBD (up to 24 hr) in GSC lines (Figs. 1c and 1d).
CBD induces TRPV2-dependent autophagy in GSCs
To determine whether the TRPV2-dependent CBD-mediated
effects in reducing GSC viability was due to activation of
autophagy, we examined the conversion of the soluble form of
LC3 (LC3-I) to the lipidated and autophagosome-associated
form (LC3-II) and the levels of the autophagy-related protein
Beclin-1.24 We found that CBD increases the cleaved LC3-II
form levels (evaluating both LC3-I/LC3-II and LC3-II/GAPDH
ratios) and the autophagy-related protein Beclin-1 (Fig. 2a). To
conﬁrm the ability of CBD to stimulate the autophagy, a
dynamic evaluation of this process was performed by the auto-
phagic ﬂux. Pretreatment of GSCs with 50 nM BAF1, which
blocks the last steps of autophagic degradation, enhanced the
CBD-induced accumulation of LC3-II protein in CBD plus
BAF1-treated GSCs, compared with single CBD or BAF1 treat-
ments (Fig. 2b). Then, the involvement of TRPV2, in CBD-
induced autophagy, was evaluated by treating GSCs with RR
and tranilast alone or in combination with CBD. The results
showed that both RR and tranilast treatments are able to com-
pletely revert the CBD-induced LC3 cleavage (Fig. 2c). To evi-
dence that the CBD effect was mediated by autophagic
pathway, we knocked-down Beclin-1 gene (Supporting Infor-
mation Fig. S3) and the CBD-mediated effect was determined
by MTT assay in siBeclin-1- and siGLO-transfected GSC lines.
As shown, the decrease of cell viability observed with CBD
treatment, was signiﬁcantly reverted in siBeclin-1- compared
with siGLO-transfected GSC lines (Fig. 2d), suggesting a role of
autophagic machinery in regulating CBD effects in GSC lines.
The molecular mechanism underlying the CBD-mediated
autophagic process, was evaluated by Autophagy Signaling
Pathway Finder PCR array analysis in GSCs cells 6 hr post-
treatment. The results showed that CBD was able to modu-
late the expression of different genes regulating the autopha-
gic and apoptotic processes, as compared with vehicle-treated
GSCs (Fig. 2e, Supporting Information Table S3).
Furthermore, we evaluated the role of the autophagic pro-
cess in the TRPV2-mediated inhibition of GSC viability by
using the autophagic inhibitors, 3-MA (5 mM) or (50 nM)
BAF1. We found that CBD inhibits the viability (Fig. 2f),
BrdU incorporation (Fig. 2h, Supporting Information Fig. S4)
and arrests the cell cycle at the G0/G1 phase (Fig. 2i), with-
out inducing cell death (Fig. 2g). Moreover, these CBD-
mediated effects were completely reverted by 3-MA (Figs. 2f-
i) and BAF1 (data not shown).
Figure 2. CBD activates the autophagic pathway. (a) Lysates from GSC #83 cells, untreated or treated with 10 lM of CBD, were separated on
14% or 10% SDS-PAGE and probed with anti-LC3 or anti-Beclin-1 Abs, respectively, and anti-GAPDH Ab. Blots are representative of one of three
separate experiments. Numbers represent the densitometric analysis. (b) Lysates from GSC #83 cells, pretreated with BAF1 (50 nM) for 1 hr and
then treated with 10 lM of CBD or vehicle for 24 hr, were separated on 14% SDS-PAGE and probed with anti-LC3 and anti-GAPDH Abs. Blots are
representative of one of three separate experiments. Numbers represent the densitometric analysis. (c) Lysates from GSC #83 cells, untreated or
pretreated with RR (10 lM) and tranilast (50 lM) for 1 hr and then treated with 10 lM of CBD or vehicle for 24 hr, were separated on 14% SDS-
PAGE and probed with anti-LC3 and anti-GAPDH Abs. Blots are representative of one of three separate experiments. Numbers represent the den-
sitometric analysis. (d) siGLO GSCs and siBeclin-1 GSCs were cultured for 24 hr with vehicle or 10 lM CBD. Cell viability was determined by MTT
assay. Data shown are expressed as mean6SD of three separate experiments; *p<0.01 vs. vehicle-treated cells; #p<0.01 CBD-treated siBe-
clin-1 GSCs vs. CBD-treated siGLO GSCs. (e) Autophagy RT profiler PCR array in mRNA samples extracted from GSCs treated for 6 hr with vehicle
or 10 lM of CBD. Values represent fold differences of individual gene expression in CBD- compared to vehicle-treated GSCs. The expression lev-
els were normalized to the average Ct value of two housekeeping genes (GAPDH and RPLP0) and calculated by the DDCt method. Graphs include
genes whose expression is, at least, 2-fold regulated. (f) GSC #83 cells were pretreated with 3-MA (5 mM) for 1 hr and then cultured for 24 hr
with CBD 10 lM or vehicle. Cell viability was determined by MTT assay. Data are expressed as mean6SD; *p<0.01 vs. vehicle; #p<0.01 vs.
CBD-treated cells. (g) Annexin-V1 and PI1 cells were determined in GSCs treated with vehicle or CBD for 24 hr by FACS analysis. Histograms are
representative of one of three separate experiments. (h) GSCs #83 were treated as above described and proliferation was assessed with the
BrdU incorporation assay. The percentage values of BrdU incorporation was reported respect to the vehicle OD. Data are expressed as
mean6SD. *p<0.01 vs. vehicle; #p<0.01 vs. CBD-treated cells. (i) GSCs #83 were cultured as above described and stained with PI solution to
assess the cell cycle distribution pattern. The values were expressed as the mean6SD of the cells percentage in each phase. *p<0.01 vs. vehi-
cle; #p<0.01 vs. CBD-treated cells. (j) GSCs were grown in soft agar for 14 days and treated with vehicle, CBD (10 lM) alone or in combination
with 3-MA (5 mM). Soft agar colony counts were done by three independent investigators microscopically visualizing individual colonies in 10
random fields. Data shown are the mean6SD of the percentage of colonies with respect to vehicle obtained in three separate. (k) Representative
immunoblots of pAKT and AKT in GSCs untreated or treated with CBD (10 lM) for up to 24 hr. GAPDH protein levels were used as loading control.
Blots are representative of one of three separate experiments. Numbers represent the densitometric analysis. (l) Representative analysis of
TRPV2 protein expression in GSCs treated with vehicle, CBD (10 lM) and Ly294002 (1 lM), alone or in combination for 24 hr. Proteins from
plasma membrane (M) and cytosolic (C) fractions were immunoblotted with anti-TRPV2 Ab. GAPDH protein levels were used as loading control.
Blots are representative of one of three separate experiments. Numbers represent the densitometric analysis. Data shown are relative to GSC
#83 line and are representative of the three GSC lines analyzed.
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Finally, we also evaluated the effect of CBD-induced
autophagy in GSC self-renewal. So, by soft agar assay we
conﬁrmed that CBD-induced autophagy affects GSCs prolif-
eration, because a signiﬁcant reduction of neurosphere for-
mation was observed in CBD- compared with vehicle-treated
GSCs, and this effect was reverted by 3-MA (Fig. 2j). In addi-
tion, since pAKT downregulation is a key signal for activa-
tion of autophagic process we evaluated the CBD effects on
pAKT. By western blot analysis we evidenced that AKT was
phosphorilated in GSC lines and CBD reduced pAKT levels
at 6 hr post-treatment, than at later times pAKT returned to
basal levels (Fig. 2k). Moreover, since the PI3K/AKT path-
ways have been found to modulate the trafﬁcking of TRPV2
to the cellular membrane, the role of PI3K signaling was fur-
ther evaluated. GSC lines were treated with LY294002 (PI3K
inhibitor, 1lM) and 24 hr post-treatments TRPV2 protein
expression was determined by western blot analysis in plasma
membrane and cytoplasm fractions. As shown, LY294002
inhibits CBD-induced increase of TRPV2 expression both in
the cytosol and plasma membrane (Fig. 2l).
CBD promotes the differentiation and sensitizes GSCs to
BCNU cytotoxic effects
The effect of CBD in inducing a differentiative phenotype
was evaluated by incubating GSC lines in proliferation
medium containing EGF and bFGF. CBD effect on modula-
tion of stem cell markers (CD133, Oct-4, SSEA-1, Nestin,
Sox2, CXCR4), differentiation markers (GFAP, bIII-tubulin)
and TRPV2 was evaluated by FACS analysis. As shown, we
found that CD133, Oct-4, SSEA-1, Nestin, Sox2 and CXCR4
were expressed although at different levels in GSC lines (Fig.
3a). In addition, a signiﬁcant decrease of CD133, Oct-4,
SSEA-1 and Nestin stem cell markers was detected in CDB-
treated compared with untreated GSC lines. As shown, CBD
reduces the expression of stem cell markers at levels compa-
rable to that found in D-GSC lines (Fig. 3a). Moreover,
increasing levels of GFAP, bIII-tubulin and TRPV2 were evi-
denced in CDB-treated compared with untreated GSCs, with
levels comparable to that found in D-GSC lines (Fig. 3a).
Next we evaluated if the CBD effect on TRPV2, GFAP and
bIII-tubulin differentiation markers, was reverted by the auto-
phagic inhibitor 3-MA. As shown, the CBD-induced expres-
sion of GFAP, bIII-tubulin and TRPV2, was reverted by 3-
MA (Fig. 3b), suggesting that the CBD-induced autophagy is
necessary to induce GSCs differentiation. Stimulation of
GSCs differentiation resulted in a reduced resistance of GSCs
to BCNU-induced cytotoxic effects.7 Thus we treated GSCs
with BCNU for 48 hr under proliferative condition (medium
containing EGF and bFGF) or under differentiative condition
(medium containing 5% FBS). We found that GSCs were
resistant to BCNU; a slight decrease in cell viability was only
observed in BCNU-treated D-GSCs, whereas CBD plus
BCNU, in proliferative medium, markedly increases the sen-
sitivity of GSCs to BCNU (Fig. 3c). Then, we investigated the
mechanisms underlying the increased cytotoxic effect induced
by BCNU plus CBD administration. By Annexin-V staining
and FACS analysis, a strong increase of the Annexin-V1 apo-
ptotic cells in BCNU plus CBD-treated GSCs, compared to
BCNU- or CBD-treated GSCs was evidenced (Fig. 3d). Over-
all, our results indicate that CBD-induced autophagy repre-
sents a prerequisite for BCNU-induced apoptotic cell death.25
Furthermore, no signiﬁcative dissipation in mitochondrial
transmembrane potential was found in BCNU- or CBD-
treated GSCs, whereas a three-fold increase was observed in
BCNU plus CBD-treated GSCs (Fig. 3e). Since TMZ is fre-
quently used in GBM therapies, we evaluated the TMZ effect
in GSC lines. As showed, we found that TMZ has no effects
alone or in combination with CBD, in GSC and D-GSC lines
(Supporting Information Fig. S5a and S5b). Moreover, we
evidenced that the resistance to TMZ is not correlate with
MGMT promoter methylation state, since MGMT promoter
in GCS #83 was unmethylated, while in GSC #1 and GSC
#30 was hypermethilated (Supporting Information Fig. S5c).
Overall, CBD inducing GSCs differentiation increases the
sensitivity to BCNU cytotoxicity by inducing mitochondrial-
dependent apoptosis.
Expression of the Aml-1 spliced variants in GSC and D-GSC
lines
The expression of Aml-1a, Aml-1b and Aml-1c was investi-
gated by qualitative PCR in the GSC lines. Results showed
three different transcripts of 205, 232 and 168 bp, respec-
tively, corresponding to Aml-1a, Aml-1b and Aml-1c spliced
variants in all the GSC lines analyzed (Fig. 4a). By qRT-PCR
Aml-1a, Aml-1b and Aml-1c relative expression was deter-
mined in all the GSC and in D-GSC lines (Figs. 4b and 4c).
As shown, we determined the Aml-1 spliced variant levels
and we found that Aml-1a mRNA is overexpressed (at 7 and
14 days of differentiation) in all the D-GSC lines, compared
with the respective GSC lines, whereas Aml-1b and Aml-1c
display a cell line-speciﬁc expression proﬁle (Fig. 4c). Since
our data demonstrated that CBD induces GSC differentiation,
we evaluated the effect of CBD, in regulating Aml-1a expres-
sion. By qRT-PCR and western blot analysis we found that
CBD increases the Aml-1a mRNA and protein expression
compared with vehicle-treated GSCs (Figs. 4d and 4e). Then,
we evaluated the role of CBD-induced TRPV2 activation in
regulating Aml-1a expression. GSC lines were treated with
RR, tranilast, LY294002 alone and in combination with CBD,
and Aml-1a nuclear levels were determined by western blot
analysis. As shown, the CBD-induced Aml-1a expression was
reduced both by RR, tranilast and LY294002, suggesting the
involvement of TRPV2 and PI3K pathways in CBD-induced
Aml-1a expression (Fig. 4e).
Then, we evaluated if the increase of TRPV2 observed in
D-GSCs was under the transcriptional control of Aml-1a.
ChIP analysis were performed in GSCs, D-GSCs and in
siAml-1 (knock-down of all siAml-1 spliced variants), and
siAml-1a silenced D-GSCs. Before ChIP assays, to assess if
gene silencing was effective in reducing the three isoforms in
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Figure 3. CBD promotes differentiation through the autophagic pathway and increases chemosensitivity of GSCs. (a) Untreated or CBD-
treated GSCs were cultured in proliferative medium containing EGF and bFGF for 48 hr. D-GSCs were cultured in differentiative medium con-
taining 5% FBS for 72 hr. CD133, Oct-4, SSEA-1, Nestin, Sox2, CXCR4, GFAP, bIII- tubulin and TRPV2 expression levels were detected by
FACS analysis. Data shown are expressed as mean fluorescence intensity (MFI) and are representative of one of three separate experiments.
(b) Lysates from GSCs, untreated or treated with 10 lM of CBD pretreated or not with 3-MA (5 mM) for 1 hr, were separated on 7% SDS-
PAGE and probed with anti-TRPV2, anti-GFAP and anti-bIII-tubulin Abs. Blots are representative of one of three separate experiments. Protein
levels were expressed as relative fold respect to GAPDH protein level used as loading control. The values indicate the density proportion of
each protein compared with vehicle. (c) GSCs were cultured for 24 hr with CBD (10 lM) and BCNU (200 lM) alone or in combination in a
proliferative medium. Moreover GSC cells were treated with BCNU (200 lM) or vehicle in a differentiative medium. Cell viability was deter-
mined by MTT assay. Data are expressed as mean6SD. *p<0.01 vs. vehicle; #p<0.01 vs. CBD-treated cells. (d) Percentage of Annexin-
V1 cells in GSCs treated with CBD (10 lM), BCNU (200 lM), alone or in combination was determined by FACS analysis. Histograms are rep-
resentative of one of three separate experiments. Data are expressed as percentage of positive cells. (e) Changes of Dwm were evaluated
in GSCs treated as above described, by JC-1 staining and biparametrice FL1 (green)/FL2 (red) flow cytometric analysis. Numbers indicate
the percentage of cells showing a drop in Dwm-related red fluorescence intensity. CCCP was used as positive control.
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siAml-1 D-GSCs and Aml-1a in siAml-1a D-GSCs we eval-
uated the protein expression of Aml-1 splice variants, in
nuclear extracts by western blot. As shown the Aml-1 iso-
form levels were higher in D-GSCs compared with both
GSCs and siAml-1 D-GSCs; moreover only Aml-1a isoform
levels were reduced in siAml-1a D-GSCs compared with both
D-GSCs and siAml-1 D-GSCs (Fig. 4f). siFluo cotransfection
was performed to conﬁrm siRNA intake in GSC lines (Sup-
porting Information Fig. S6). So gene silencing results dem-
onstrated the speciﬁcity of both siAml-1 and siAml-1a. By
ChIP analysis we assessed whether and which Aml-1 isoform
direcly contributes to TRPV2 transcription. We found an
increase of TRPV2 sites IP fold enrichment in D-GSCs (3.5
(1)01Kb, 5.0 (1)08Kb) compared with GSCs and a decrease
Figure 4:
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of these sites in both siAml-1 D-GSCs (0.3 (1)01Kb, 0.8
(1)08Kb) and siAm-1a D-GSCs (0.6 (1)01Kb, 0.9 (1)08Kb;
Fig. 4g). These results indicated that Aml-1a binds to TRPV2
gene promoters, and this interaction enhances TRPV2 tran-
scription. In fact, TRPV2 site IP fold lower levels were
detected during siAml-1 and siAml-1a gene silencing in D-
GSCs compared with siGLO D-GSCs, indicating that Aml-1a
is the main isoform bound to the TRPV2 promoter region
during GSCs differentiation.
Silencing of Aml-1a spliced variant promotes self renewal
and proliferation and inhibits the differentiation of GSCs
To demonstrate the involvement of Aml-1a in the modula-
tion of GSCs proliferation and self renewal capability and dif-
ferentiation, we knock-down the Aml-1a gene during the
GSCs differentiation. Transfection with siAml-1a markedly
reduced the Aml-1a expression, both at mRNA (about 70%)
and protein level (about 60%), evaluated at day 7 of differen-
tion (Supporting Information Fig. 6). Moreover, by MTT
assay, BrdU incorporation and clonogenic assays, we found
that silencing of Aml-1a in D-GSCs increases the GSCs via-
bility (Fig. 5a), the percentage of BrdU1 cells from 49% to
67% (Fig. 5b) and the number of total colonies growth in
soft agar compared with siGLO-transfected D-GSCs, respec-
tively (Fig. 5c). Moreover, a reduced expression of TRPV2,
GFAP and bIII-tubulin was found in siAml-1a D-GSC com-
pared with siGLO D-GSC lines (Fig. 5d). No changes in Nes-
tin and Sox2 expression were found in siAml-1a- vs. siGLO
D-GSCs (Fig. 5d). In addition, we analyzed the expression of
84 genes involved in signal transduction pathways important
for stem cell maintenance, proliferation and/or differentia-
tion, in siAml-1a- and siGLO-transfected D-GSC lines, by a
Stem Cell Signaling Pathway Finder PCR array. The results
showed that Aml-1a gene silencing in GSCs signiﬁcantly
induces the expression of 5 genes as well as 20 other genes
are upregulates (Table 1), suggesting that lost of Aml-1a
expression promotes a genetic transcriptional program con-
fering to the D-GSCs a less differentiated stem cell and more
proliferative phenotype, indicating that Aml-1a splice variant
impairs the proliferation and promotes the differentiation in
GSCs.
Discussion
The malignant phenotype of GBM is believed to be largely
driven by GSCs, and targeting GSCs is now considered a
promising new approach for GBM treatment.26,27 Cannabi-
noids have been demonstrated to act as antitumour agents in
human GBM cell lines, both in vitro and in vivo,11,28 and to
decrease the efﬁciency of GSCs to initiate glioma formation.14
In particular, CBD has been shown to inhibit survival and
proliferation,24 to induce cell death and chemosensitizing
effects in human GBM and other cancer cell lines in a CB
receptor-independent and TRPV2-dependent manner.11,29,30
Herein, we demonstrated that CBD through TRPV2 acti-
vation induces autophagy in GSCs. The autophagy genes acti-
vated by CBD include ULK2, Atg9B, ATG10, Beclin-1,
GARABAP, ATG16 L2, PI3CG and RAB24 genes. In addi-
tion, we found that CBD-induced autophagy in GSCs may be
the result of changes in the expression of eukaryotic initiator
factors (eIFs) of unfolded protein response. Translation of
mRNAs that affect stress-mediated differentiation, cellular
growth, apoptosis and autophagy is regulated by the AKT/
mTOR protein kinase network and requires the recruitment
of the eIF4F complex (the cap-binding protein eIF4E, the
scaffolding protein eIF4G and an ATP-dependent RNA heli-
case eIF4A). Downregulation and upregulation of the eIF4GI
and eIF2AK3, respectively were found in CBD-treated GSCs.
Autophagy activation via the CBD/TRPV2 pathway inhib-
ited viability and proliferation, arrested the cell cycle at the
G0/G1 phase and promoted the activation of a differentiation
program as evaluated by the increase of the expression of
GFAP and bIII-tubulin differentiation markers in GSCs.
These effects were inhibited by the cotreatment with auto-
phagic blockers, suggesting that CBD induces differentiation
of GSCs throught the autophagic pathway. Similarly, the
autophagic activator, rapamycin promotes differentiation of
glioma stem/progenitor cells (GSPGs), and 3-MA and BAF1
inhibited the FBS-induced differentiation of GSPGs.9
Figure 4. Aml-1a expression increases during GSCs differentiation and binds TRPV2 promoter. (a) Representative agarose gel electrophore-
sis of Aml-1 isoforms mRNA expression evaluated by qualitative PCR in GSC #83 line. (b) The relative Aml-1 isoforms mRNA expression in
GSCs #1, #30 and #83 was evaluated by qRT-PCR. Aml-1 mRNA levels were normalized for b-actin expression. Data are expressed as
mean6SD. (c) Aml-1 isoforms mRNA expression in D-GSC lines (day 7 and 14 of differentiation) was evaluated by qRT-PCR and was
expressed as relative fold with respect to the corresponding GSC lines used as calibrator. Data are expressed as mean6SD; *p<0.01 D-
GSCs vs. GSCs. (d) Aml-1 isoforms mRNA expression in 24 hr vehicle- and CBD-treated GSCs was evaluated by qRT-PCR and was expressed
as relative fold with respect to vehicle-treated cells. Data are expressed as mean6SD; *p<0.01 CBD- vs. vehicle-treated. (e) Lysates from
GSCs treated with vehicle, CBD (10 lM) pretreated or not with RR (10 lM), tranilast (50 lM) or LY294002 (1 lM) for 1 hr, were separated
on 10% SDS-PAGE and probed with anti-Aml-1 and anti-GAPDH Abs. Blots are representative of one of three separate experiments. Num-
bers represent the densitometric analysis. (f) Nuclear fractions from GSCs and from siGLO D-GSCs, siAml-1 D-GSCs and siAml-1a D-GSCs at
day 7 of differentiation were immunoblotted with Aml-1 Ab and the relative isoforms protein levels were determined using TFIIB protein lev-
els as loading control. To detect Aml-1b,c and Aml-1a variants, 10% and 12% SDSPAGE gels were performed, respectively. Blots shown are
representative of one of three separate experiments. Bar graphs represent the mean6SD of at least three separate experiments, *p<0.01
vs. GSCs; #p<0.01 vs. iGLO D-GSCs. (g) ChIP analysis of GSCs and of siGLO D-GSCs, siAml-1 D-GSCs and siAml-1a D-GSCs cultured for 7
days in differentiation conditions. DNA immunoprecipitated by using Aml-1 Ab directed against all three isoforms was amplified by qRT-
PCR. Data are expressed as mean6SD of three independent experiments, *p<0.01 vs. GSCs, #p<0.01 vs. iGLO D-GSCs. Data shown are
relative to GSC #83 line and are representative of the three GSC lines analyzed.
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The autophagy promoting activity of CBD in GSCs seems
to be regulated by the AKT-PI3k/RPS6KBI/PTEN pathway.
In fact, downregulation of the prosurvival kinase AKT, and
upregulation of PTEN, the negative controller of AKT activ-
ity and of PIK3CG kinase were found in CBD-treated GSCs.
Moreover, the AKT/mTOR network positively regulates the
activity of the mTORC1 complex and AKT inhibition
decreases mTORC1 activity and promotes autophagy.31
Herein, we found that CBD reduces AKT activity in GSC
lines, by decreasing pAKT levels, further supporting the role
of CBD in regulating autophagy in GSC lines.
Speciﬁc markers of autophagic process were LC3 conver-
sion to LC3-II that correlate with the number of autophago-
somes and Beclin-1/PI3K-III complex that is involved in the
formation of autophagosomes.9 Furthermore, Beclin-1 was
found to confer both autophagy and differentiation in cancer
cells.8 The increase of PIK3CG and LC3-II/LC3-I ratio levels
in CBD-treated GSCs, strongly supports for the Beclin-1-
PIK3C3 complexes formation, required for the recruitment of
autophagic effectors.32 This evidence was supported in
siBeclin-1 GSC lines where CBD effect on cell viability was
reverted. Moreover, a decrease of pAKT levels evidenced in
CBD-treated GSC lines correlates with activation of autopha-
gic process.
Autophagic pathways induces differentiation in GSC lines,
and autophagic inhibitors stimulates GSCs differentiation.9
Herein, we evidenced that CBD via activation of autophagy
induces expression of differentiation markers as GFAP,14
bIII-tubulin
14 and decreases expression of stem cell markers
as CD133,33 Oct-4,34, SSEA-135 and Nestin.14
Several reports have studied the therapeutic effect of the
use of pro-differentiating agents on GSCs, because of their
capability to elicit chemosensitizing effects and increment the
susceptibility of GSCs to drug cytotoxic.8 Previous studies
Figure 5. Aml-1a regulates proliferation and differentiation of GSCs. (a) siGLO and siAml-1a GSCs were cultured up to 7 days under differ-
entiation conditions (D-GSCs). Cell viability was determined by MTT assay. Data shown are expressed as mean6SD of three separate
experiments; *p<0.01 vs. siGLO D-GSCs. (b) siGLO and siAml-1a D-GSCs were cultured as above described and proliferation was assessed
by the BrdU incorporation assay. BrdU was added 24 hr before the harvesting of cells. Cells were stained for BrdU incorporation and ana-
lyzed by FACS. The position of M1 (BrdU1 marker) was determined by a BrdU(-) control, dark curve. Percentages indicate the number of
cells that are positive for BrdU in the total sample size. (c) siGLO and siAml-1a D-GSCs were grown in soft agar for 14 days. Soft agar col-
ony counts were done by three independent investigators microscopically visualizing individual colonies in 10 random fields. Data shown
are the mean6SD of colony counts obtained in three separate experiments. *p<0.01 vs. siGLO DGSCs. (d) Immunoblots of TRPV2, GFAP,
bIII-tubulin, Nestin and SOX2 protein expression in siGLO D-GSCs and siAml-1a D-GSCs. GAPDH protein levels were used as loading control.
Bar graphs represent the mean6SD of at least three separate experiments, *p<0.01 vs. siGLO D-GSCs. Data shown are relative to GSC
#83 line and are representative of the three GSC lines analyzed.
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demonstrated that GSCs are resistant to conventional chemo-
therapeutic drugs as BCNU.7 In addition, treatments to
increase the differentiation GSCs status result in an higher sen-
sitivity of GSCs to chemotherapeutical drugs.36 CBD treat-
ments increase BCNU and TMZ chemosensitivity in GBM cell
lines and combined administration of THC or THC plus CBD
with TMZ synergistically reduces the growth of glioma xeno-
grafts.27 Herein, we found that treatment of GSC with CBD
alone doesn’t induce apoptosis, but it sensitizes GSCs to
BCNU-induced apoptosis. Concordingly downregulation of
BCL-XL and CTDS mRNAs involved in drug resistance in
GBM, and upregulation of BAD and BAX mRNAs restoring
the sensitivity to apoptotic stimuli and increasing the sensitiv-
ity to chemotherapy in certain glioma cell types,37 were found
in CBD-treated GSCs. About TMZ, we conﬁrm, as previously
reported7,38 that GSCs are resistant to TMZ chemotherapy.
Aml-1 proteins have been shown as crucial transcription
factors inﬂuencing a wide range of biological processes, by
regulating signaling pathways involved in self renewal, cell
proliferation and differentiation.17. Herein, we found that all
the Aml-1a, Aml-1b and Aml-1c spliced variants analyzed
are expressed, although at different level, in the three GSCs
lines, but only the Aml-1a variant is upregulated in all the
GSC lines analyzed, with a marked accumulation of the Aml-
1a protein at nuclear level after GSC differentiation. Treat-
ment of GSCs with CBD, that increases TRPV2 expression,
induces Aml-1a mRNA upregulation, suggesting that CBD-
induced effects on GSCs differentiation could be partially the
result of a CBD-induced Aml-1a transcription. Although
Aml-1 has been shown to be critically in maintenance of pro-
genitor cells as well as in their differentiation, the contribute
of Aml-1a, as respect to the other spliced variants is not yet
fully understood.17 Aml-1a plays a role in erythroid and meg-
akaryocytic differentiation39; in myeloid cells, Aml-1a by
repressing the transcription of the macrophage colony-
stimulating factor receptor mediated by Aml-1b, blocked the
differentiation.40 We previously demonstrated that TRPV2
over-expression promotes differentiation and inhibits prolif-
eration in GSCs,11 but the transcriptional regulation of
Table 1. siAml-1a influences stem cell signaling pathway
Gene
symbol Fold SD
Gene
symbol Fold SD
ACVR1 1.0 0.20 LTBP4 4.8 0.12
ACVR1B 1.0 0.20 NCSTN 1.4 0.11
ACVR1C 1.0 0.30 NFAT5 1.8 0.11
ACVR2A 16.5 0.10 NFATC1 2.1 0.12
ACVR2B 1.5 0.30 NFATC2 1 0.11
ACVRL1 1.0 0.30 NFATC3 1.2 0.11
AMHR2 1.0 0.20 NFATC4 1.8 0.12
BCL9 1.8 0.30 NOTCH1 1.7 0.10
BCL9L 1.9 0.30 NOTCH2 4.5 0.13
BMPR1A 5.8 0.12 NOTCH3 11.5 0.14
BMPR1B 1.0 0.20 NOTCH4 2.1 0.10
BMPR2 1.0 0.22 PSEN2 1.7 0.11
CDX2 1.0 0.25 PSENEN 1.2 0.11
CREBBP 2.5 0.13 PTCH1 1.6 0.11
CTNNB1 2.6 0.12 PTCHD2 1 0.09
E2F5 1.0 0.29 PYGO2 1 0.11
ENG 1.0 0.29 RBL1 3.3 0.13
EP300 2.3 0.40 RBL2 1.8 0.10
FGFR1 3.4 0.18 RBPJL 1 0.11
FGFR2 induced
(1.8)*
0.13 RGMA 1.5 0.08
FGFR3 induced
(3.3)*
0.10 SMAD1 1.4 0.10
FGFR4 induced
(3.2)*
0.11 SMAD2 1.5 0.12
FZD1 3.7 0.11 SMAD3 2.1 0.12
FZD2 1 0.11 SMAD4 2.0 0.12
FZD3 6.2 0.11 SMAD5 2.7 0.15
FZD4 1.5 0.10 SMAD6 5.3 0.14
FZD5 1 0.11 SMAD7 2.0 0.16
FZD6 5.3 0.13 SMAD9 5.9 0.18
FZD7 2.2 0.14 SMO 1.3 0.09
FZD8 2.5 0.10 SP1 1.3 0.11
FZD9 1 0.20 STAT3 2.0 0.10
GLI1 induced
(2.2)*
0.11 SUFU 1.9 0.13
GLI2 induced
(2.8)*
0.11 TCF7 2.2 0.16
GLI3 4.4 0.10 TCF7L1 3.3 0.12
IL6ST 3.6 0.11 TCF7L2 3.7 0.11
LEF1 2.2 0.12 TGFBR1 1.8 0.10
LIFR 6.5 0.11 TGFBR2 1 0.10
LRP5 1 0.11 TGFBR3 1.6 0.09
LRP6 1.8 0.11 TGFBRAP1 1.3 0.08
LTBP1 1 0.11 VANGL2 1.9 0.10
Table 1. siAml-1a influences stem cell signaling pathway
(Continued)
Gene
symbol Fold SD
Gene
symbol Fold SD
LTBP2 2.2 0.12 ZEB2 4.0 0.11
LTBP3 1.5 0.10
Stem Cell Signaling Pathway Finder PCR array in mRNA samples
extracted from siGLO D-GSCs and siAml-1a D-GSCs after 7 days of cul-
ture. Values represent fold differences of individual gene expression in
siAml-1a D-GSCs compared to siGLO D-GSCs. The expression levels
were normalized to the average Ct value of two housekeeping genes
(GAPDH and RPLP0) and calculated by the DDCt method. Genes, whose
expression is, at least, 2.5-fold upregulated, are in bold.
Data shown are relative to GSC #83 line and are representative of the
three GSC lines analyzed.
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TRPV2 gene in GSCs was not investigated. Since, Aml-1
(although no information about which spliced variant is
involved) has been found to increase expression of several
ion channels as TRPV1, TRPA1 and TRPM8,41 we evaluated
if Aml-1a was involved in TRPV2 transcription. So by CHIP
analysis in siAml-1 and in siAml-1a transfected D-GSCs we
demonstrated that TRPV2 upregulation in D-GSC lines
requires Aml-1a, since its abrogation reduces TRPV2 pro-
moters activity resulting in downregulation of TRPV2 expres-
sion levels.
Silencing of Aml-1a during GSC differentiation stimulates
self renewal capability, with an increased total colony num-
bers, enhances cell viability and proliferation, and reduces the
expression of the GFAP, bIII-tubulin and TRPV2 differentia-
tion markers, whereas no changes of Sox2 and Nestin were
found. Thus, Aml-1a silencing of at day 7 of differentiation
strongly inhibits GSCs astroglial differentiation promoting
GSCs proliferation, stemness and pluripotency. These proc-
esses are deﬁned by number of key signal transduction path-
ways that are regulated by a stem cell transcription factors.
Here, we found that Aml-1a silencing activates a mitogenic
signaling pathways in GSCs. Thus, FGFR2, FGFR3 and
FGFR4 and GLI1 and GLI2 glioma-associated transcription
genes belonging to FGF and Hedgehog pathways were ex-
novo induced. FGF and EGF are the main recombinant
growth factor in GSC medium.42 Gli1, Gli2 and Gli3 are exe-
cuters of Sonic Hedgehog (Shh) signaling and targets the
TGFb signaling axis.43 They are indispensable for glioma-
initiating cells (GICs) proliferation and Shh inhibitors pre-
vented GIC proliferation. Increased NOTCH2/3 mRNA
expression was found in siAml-1a GSCs. Activation of
NOTCH signaling in GSCs enhanced colony formation capa-
bility and increased self-renawal and dedifferentiation; in par-
ticular, NOTCH3 stimulates glioma cell proliferation, cell
migration, invasion and apoptosis.44 Increased proliferation
observed in siAml-1a GSCs is also the result of upregulation
of ACVR2A, BMPR1A, LTBP4 and SMAD6,9 belonging to
BMP and TGFb superfamily. ACVR2A regulates proliferation
in neurosensory tissues.45 BMP/BMPR1A/B pathway inhibits
the differentiation of glioblastoma tumor initiating cells.46
Latent transforming growth factor binding proteins (LTBPs)
are involved in the regulation of mesenchymal cell func-
tions47 and TGFb biodisponibility.48 Wnt/frizzled (FZD) cas-
cades control cell fate, proliferation and migration. A high
level of CTNNB1 (Wnt/b-catenin), its frizzled receptors
FZD1, FZD3 and FZD649 and the b-catenin coactivators
TCFL1 and TCFL2 which increase GBM proliferation,50 were
found in siAml1-a GSCs. We also found that both IL-6ST/
gp130 and LIFR implicated in GSC pluripotency maintei-
nance and self-renewal51 and the vertebrate zinc ﬁnger E-box
binding homeobox-2 (ZEB2), that suppresses the E-cadherin
expression and differentiation as well as stimulates prolifera-
tion, migration and invasion,52 were upregulated in siAml-1a
GSCs.
In summary, in this study we identify a potential new
pathway that links the activation of autophagy to differentia-
tion, which promotes molecular events that sensitize GSCs
to the apoptotic death. Moreover, a relevant role was
ascribed to Aml-1a variant in the induction of GSC differen-
tiation. Therefore, understanding of the exact mechanism of
Aml-1 variants implicated in the regulation GSC self-
renewal, proliferation and differentiation will provide tools
for the development of more successful therapeutic
strategies.
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